A detailed history of Cubist Systematic Strategies, LLC transactions in Liquidia Corp stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 118,200 shares of LQDA stock, worth $1.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
118,200
Previous 118,200 -0.0%
Holding current value
$1.3 Million
Previous $1.42 Million -0.0%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$11.35 - $16.73 $960,255 - $1.42 Million
-84,604 Reduced 31.13%
187,176 $2.76 Million
Q4 2023

Feb 14, 2024

BUY
$5.77 - $12.19 $1.26 Million - $2.66 Million
217,821 Added 403.68%
271,780 $3.27 Million
Q3 2023

Nov 14, 2023

BUY
$6.27 - $8.15 $230,359 - $299,431
36,740 Added 213.37%
53,959 $342,000
Q2 2023

Aug 14, 2023

SELL
$6.63 - $9.9 $40,323 - $60,211
-6,082 Reduced 26.1%
17,219 $135,000
Q1 2023

May 15, 2023

BUY
$5.72 - $7.91 $133,281 - $184,310
23,301 New
23,301 $161,000
Q3 2022

Nov 14, 2022

SELL
$3.73 - $8.39 $581,342 - $1.31 Million
-155,856 Reduced 79.89%
39,242 $213,000
Q2 2022

Aug 15, 2022

BUY
$3.37 - $7.55 $458,350 - $1.03 Million
136,009 Added 230.18%
195,098 $851,000
Q1 2022

May 16, 2022

BUY
$5.14 - $7.38 $129,353 - $185,725
25,166 Added 74.19%
59,089 $424,000
Q4 2021

Feb 14, 2022

BUY
$2.71 - $5.17 $91,931 - $175,381
33,923 New
33,923 $165,000
Q2 2021

Aug 16, 2021

SELL
$2.51 - $3.11 $25,702 - $31,846
-10,240 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$2.42 - $3.6 $24,780 - $36,864
10,240 New
10,240 $28,000
Q3 2020

Nov 16, 2020

SELL
$4.34 - $8.28 $1,302 - $2,484
-300 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$4.86 - $11.44 $1,458 - $3,432
300 New
300 $3,000

Others Institutions Holding LQDA

About Liquidia Corp


  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $709M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.